Freeline Therapeutics (FRLN) IPO Prices at $18

Freeline Therapeutics Holdings plc, announced the pricing of its initial public offering in the United States of 8,823,529 American Depositary Shares (“ADSs”) representing 8,823,529 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of approximately $158.8 million. All ADSs sold in the offering were offered by Freeline. The ADSs are expected to begin trading on The Nasdaq Global Select Market on 7 August 2020 under the ticker symbol “FRLN.” In addition, Freeline has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on 11 August 2020, subject to customary closing conditions.

J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering. Wedbush Securities Inc. is acting as lead manager.

Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the U.K. and has operations in Germany and the U.S.

You May Also Be Interested In

• JPMorgan on SpaceX-Tesla merger: strategically sound but overly complex
• Freedom Metals Acquisition prices $275M IPO on Nasdaq
• BingX Launches SK Hynix ADR Pre-IPO Trading with a $100,000 Prediction Campaign